In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xellia Pharmaceuticals Aps

http://xellia.com

Latest From Xellia Pharmaceuticals Aps

Xellia CEO Questions Key Ingredients Reliance Of US And Europe

In an exclusive interview with Generics Bulletin, the CEO of API and FDF manufacturer Xellia Pharmaceuticals, expresses concern over supply chain resilience of the US and the EU, as he points out the weaknesses exposed by the pandemic. The company has also announced the release of its first anti-infectives manufactured at its newly operational Cleveland site. 

Generic Drugs Manufacturing

When You Can’t Win For Losing: Kodak And The Reshoring Of US Pharmaceutical Manufacturing

Kodak, Fujifilm and startups Civica Rx and Phlow fight with grit, vision and government support to restore US pharmaceutical manufacturing.

Business Strategies Ingredients

Xellia Joins Medicines For Europe

With a commitment to make drug products affordable and accessible in Europe, Xellia has joined off-patent industry association Medicines for Europe.

Europe Generic Drugs

Caplin Partners With Xellia For Five Injectables

With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.

Deals Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Pharmaero
UsernamePublicRestriction

Register